Thesis, COLLÉGIALITÉ
Devos, Zoé
Promoteur(s) : Herfs, Michael
Date de soutenance : 4-sep-2023 • URL permanente : http://hdl.handle.net/2268.2/18006
Détails
Titre : | Thesis, COLLÉGIALITÉ |
Titre traduit : | [fr] Identifier les Vulnérabilités Sélectives associées aux Mutations Perte de Fonction de NOTCH dans le Cancer du Poumon à Petites Cellules |
Auteur : | Devos, Zoé |
Date de soutenance : | 4-sep-2023 |
Promoteur(s) : | Herfs, Michael |
Membre(s) du jury : | Nokin, Marie-Julie
Deroanne, Christophe Blomme, Arnaud |
Langue : | Anglais |
Nombre de pages : | 46 |
Mots-clés : | [en] Small Cell Lung Cancer [en] Neuroendocrine [en] NOTCH [en] NOTCH2 [en] Loss-of-function Mutations [en] NOTCH LOF Mutations [en] CRISPR-Cas9 [en] POU2F3 [en] C11ORF53 [en] COLCA1 [en] COLCA2 [en] SCLC-P [en] SCLC-A [en] Synthetic Lethality [en] dTAG [en] GEMM [en] TRIM28 [en] ERV [en] MYC-L [en] Dependencies [en] CRISPR-Cas9 KO |
Discipline(s) : | Sciences de la santé humaine > Oncologie |
Centre(s) de recherche : | Oser Laboratory - Department of Medical Oncology - Dana Farber Cancer Institute |
Public cible : | Chercheurs Professionnels du domaine |
Institution(s) : | Université de Liège, Liège, Belgique |
Diplôme : | Master en sciences biomédicales, à finalité approfondie |
Faculté : | Mémoires de la Faculté de Médecine |
Résumé
[en] Small cell lung cancers (SCLCs) are highly aggressive neuroendocrine (NE) malignancies, accounting for 15% of all lung cancers. In addition to nearly universal loss of TP53 and RB1 tumour suppressor genes, 20-25% of SCLCs tumors carry loss-of-function (LOF) mutations within members of the NOTCH receptors family genes. Those mutations, drivers of SCLC, are often considered undruggable, there is therefore no effective targeted therapies for SCLC.
Herein, we investigated selective vulnerabilities of SCLC carrying NOTCH LOF mutations, with an aim to lay a preclinical foundation to develop target therapies for SCLC tumors. We mainly worked in vitro with human and murine cells derived from SCLC tumors, which we genetically modified by CRISPR-Cas9- mediated knockouts (KO). We approached the subject from two angles of research :
1 NOTCH LOF mutation as a driver of the POU2F3-C11ORF53/COLCA2 complex
First, we focused on the dependencies of non-neuroendocrine SCLC-P subtypes, expressing the key transcription factor POU2F3. SCLC-Ps are thought to depend on either transcriptional cofactors C11ORF53 or COLCA2. We studied the dependencies of different cell lines carrying or not NOTCH2 loss- of-function mutation. Finally, we hypothesized that C11ORF53 and POU2F3 formed a complex in all SCLC-Ps, regardless of their dependence on one cofactor or the other, since this complex would itself be dependent on C11ORF53.
2 NOTCH LOF mutations as a vulnerability synthetically lethal with TRIM28
Secondly, we validated a dTAG system applying to TRIM28 in vitro in neuroendocrine SCLC cells (SCLC- A) derived from genetically engineered mice (GEMMs). With this model we investigated the synthetic lethal interaction between NOTCH2 and TRIM28 in SCLC cells, previously described by Dr. Hong. In this context, we investigated how NOTCH participates in the repression of endogenous retroviruses (ERVs), as TRIM28 mainly function as a repressor of ERVs. We notably observed that the absence of TRIM28 decreased MYC-L expression, a key linage transcription factor of SCLC-A.
Fichier(s)
Document(s)
Description: -
Taille: 11.34 MB
Format: Adobe PDF
Citer ce mémoire
L'Université de Liège ne garantit pas la qualité scientifique de ces travaux d'étudiants ni l'exactitude de l'ensemble des informations qu'ils contiennent.